Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Rare Tumour × Irinotecan × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 13 Rectal Neoplasms 4 Colonic Neoplasms 3 Pancreatic Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Stomach Neoplasms 1 Solid Tumors 1 Rhabdomyosarcoma 1 Rare Tumour 1 Pathologic Complete Response 1 Pancreatic Cancer Resectable 1 Neoplasms, Second Primary 1 Neoplasm, Residual 1 Medulloblastoma 1 Lung Neoplasms 1 Locally Advanced Low Rectal Adenocarcinoma 1 Esophageal Neoplasms 1 Cirrhosis, Familial, with Pulmonary Hypertension 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Cancer Metastatic 1 Appendiceal Neoplasms 1 Advanced Esophageal Carcinoma 1

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡